Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine

Medical Microbiology and Immunology

Volumn 204, Issue 1, 2015, Pages 57-68

  Shouval, Daniel ^a   Roggendorf, Hedwig ^b   Roggendorf, Michael ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hepatitis B vaccine; Immunogenicity; Pre S1 Pre S2 S; Prevention of hepatitis B; Recombinant HBV vaccines; Sci B Vac

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B VACCINE; PROTEIN PRECURSOR; RECOMBINANT VACCINE;

ANTIBODY TITER; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; KIDNEY FAILURE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VACCINATION; VIRUS REPLICATION; IMMUNOLOGY; PROCEDURES; VIET NAM;

HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; PROTEIN PRECURSORS; VACCINATION; VACCINES, SYNTHETIC; VIETNAM;

EID: 84925486426     PISSN: 03008584     EISSN: 14321831     Source Type: Journal    
DOI: 10.1007/s00430-014-0374-x     Document Type: Review

References (82)

1. Zanetti AR, Van Damme P, Shouval D (2008) The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26:6266–6273
2. Shouval D (2003) Hepatitis B vaccines. J Hepatol 39(Suppl 1):S70–S76
3. Zuckerman JN, Zuckerman AJ, Symington I, Du W, Williams A, Dickson B, Young MD (2001) Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 34:798–802
4. Yum JS, Ahn BC, Jo HJ, Kim DY, Kim KH, Kim HS, Sung YC, Yoon J, Morrey J, Moon HM (2012) Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection. Clin Vaccine Immunol 19:120–127
5. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brecho C (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34:917–921
6. Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH (1994) Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12:1453–1459
7. Kubba AK, Taylor P, Graneek B, Strobel S (2003) Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 6:106–112
8. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G (2004) Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 20:1053–1062
9. Laurence JC (2005) Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 118(Suppl 10A):75S–83S
10. Aziz A, Aziz S, Li DS, Murphy L, Leone N, Kennedy M, Dhillon S, Van Thiel DH (2006) Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 13:217–221
11. Fabrizi F, Dixit V, Bunnapradist S, Martin P (2006) Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther 23:1105–1112
12. Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH (2009) Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 20:595–600
13. Alavian SM, Tabatabaei SV (2010) The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine 28:3773–3777
14. Gisbert JP, Chaparro M, Esteve M (2011) Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 33:619–633
15. Fabrizi F, Dixit V, Martin P, Jadoul M, Messa P (2012) Meta-analysis: the impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease. Dig Dis Sci 57:1366–1372
16. Vitaliti G, Pratico AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S (2013) Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 19:838–845
17. Kamath GR, Shah DP, Hwang LY (2014) Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine 32:2265–2274
18. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ (1989) Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321:708–712
19. Li ZK, Nie JJ, Li J, Zhuang H (2013) The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 31:4355–4361
20. Milich DR, Hughes JL, Mclachlan A, Thornton GB, Moriarty A (1988) Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci USA 85:1610–1614
21. Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M (1986) A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 83:9174–9178
22. Leroux-Roels G, Desombere I, De Tollenaere G, Petit MA, Desmons P, Hauser P, Delem A, De Grave D, Safary A (1997) Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 15:1724–1731
23. Fujisawa Y, Kuroda S, Van Eerd PM, Schellekens H, Kakinuma A (1990) Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine 8:192–198
24. Sanyal G, Shi L (2009) A review of multiple approaches towards an improved hepatitis B vaccine. Expert Opin Ther Pat 19:59–72
25. Pollicino T, Cacciola I, Saffioti F, Raimondo G et al. (2014) Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 61:408–417
26. Zuckerman JN (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169–177
27. Laub O, Rall LB, Truett M, Shaul Y, Standring DN, Valenzuela P, Rutter WJ (1983) Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region. J Virol 48:271–280
28. Madalinski K, Sylvan SP, Hellstrom U, Mikolajewicz J, Zembrzuska-Sadkowska E, Piontek E (2001) Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine 20:92–97
29. Hellstrom UB, Madalinski K, Sylvan SP (2009) PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. Virol J 6:7
30. Sylvan SP, Madalinski K, Hellstrom UB (2009) Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine. Vaccine 28:446–451
31. Diminsky D, Schirmbeck R, Reimann J, Barenholz Y (1997) Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 15:637–647
32. Diminsky D, Moav N, Gorecki M, Barenholz Y (1999) Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18:3–17
33. Yap I, Guan R, Chan SH (1992) Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein—a preliminary study on immunogenicity. Vaccine 10:439–442
34. Yap I, Guan R, Chan SH (1995) Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 10:51–55
35. Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon YL, Koren R, Shouval D (1996) Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepat 3:37–42
36. Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R (1997) Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 16:587–592
37. Shapira MY, Zeira E, Adler R, Shouval D (2001) Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 34:123–127
38. Raz R, Dagan R, Gallil A, Brill G, Kassis I, Koren R (1996) Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 14:207–211
39. Weinstein T, Chagnac A, Boaz M, Ori Y, Herman M, Zevin D, Schmilovitz-Weiss H, Gafter U (2004) Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract 97:c67–c72
40. Wilson JN, Nokes DJ, Medley GF, Shouval D (2007) Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Vaccine 25:3705–3712
41. Schumann A, Fiedler M, Dahmen U, Grosse-Wilde H, Roggendorf M, Lindemann M (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14:592–598
42. Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H (2006) Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24:2781–2789
43. Yap I, Chan SH (1996) A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Ann Acad Med Singapore 25:120–122
44. Lo CM, Lau GK, Chan SC, Fan ST, Wong J (2007) Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7:434–439
45. Krawczyk A, Roggendorf H, Ludwig C, Herzer K, Gerken G, Horn PA, Roggendorf M, Lindemann M (2013) Therapeutic vaccination of a liver transplant recipient suffering from fulminant hepatitis B during pregnancy. Liver Transplant 19:1411–1412
46. Shouval D, Adler R, Ilan Y (1993) Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. Hepatology 17:955–959
47. Dahmen U, Li J, Gu Y, Doebel L, Fan LM, Polywka S, Dirsch O, Broelsch CE (2003) The efficiency of humoral immune transfer depends on both the graft and the immunosuppressive treatment. Transpl Int 16:161–167
48. Dahmen U, Dirsch O, Li J, Fiedle M, Lu M, Rispeter K, Picucci M, Broelsch CE, Roggendorf M (2004) Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965–972
49. Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104:1818–1821
50. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, Lam SK (1997) Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25:1497–1501
51. Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, Nanji A, Yuen ST, Williams R, Naoumov NV (2002) Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122:614–624
52. Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J (2007) Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transplant 13:71–79
53. Schumann A, Lindemann M, Valentin-Gamazo C, Lu M, Elmaagacli A, Dahmen U, Knop D, Broelsch CE, Grosse-Wilde H, Roggendorf M, Fiedler M (2009) Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 87:103–111
54. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104–1108
55. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049
56. Urban S, Bartenschlager R, Kubitz R, Zoulim F (2014) Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147:48–64
57. Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61:1754–1764
58. Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel ML (1999) Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15–26
59. Horiike N, Akbar SMF, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M (2005) In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32:156–161
60. Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ (1995) Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345:1575–1576
61. Wen Y, Wang X, Wang B, Yuan Z (2014) Vaccine therapies for chronic hepatitis B: can we go further? Front Med 8:17–23
62. Heathcote J, Mchutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30:531–536
63. Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saidi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S (2015) Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 64:139–147
64. Michel ML, Mancini-Bourgine M (2005) Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 34(Suppl 1):S108–S114
65. Michel ML, Deng Q, Mancini-Bourgine M (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54:1286–1296
66. Roggendorf M, Schulte I, Xu Y, Lu M (2007) Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model. J Viral Hepat 14(Suppl 1):51–57
67. Inchauspe G, Bach G, Martin P, Bonnefoy JY (2009) Vaccination against hepatitis B and C: towards therapeutic application. Int Rev Immunol 28:7–19
68. Liu J, Kosinska A, Lu M, Roggendorf M (2014) New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin 29:10–16
69. Bertoletti A, Gehring A (2009) Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 3:561–569
70. Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F (2013) The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum Vaccin Immunother 9:1661–1672
71. Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342
72. Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, Ece A, Ozkan T, Ozeke T, Yagci RV, Haspolat K (2003) Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 22:345–349
73. Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, Furutani M, Yamasaki T, Korenaga K, Yamashita S, Konishi T, Okita K (2003) Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 71:376–384
74. Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597
75. Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Yuan ZH, Wang B, Zhao K, Wen YM (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450–456
76. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C (2012) Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143(963–73):e9
77. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968–975
78. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595–605
79. Gotsman I, Beinart R, Alper R, Rabbani E, Engelhardt D, Ilan Y (2000) Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. Antiviral Res 48:17–26
80. Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N, Segol O, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y (2003) Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 98:2505–2515
81. Hoa PT, Huy NT, Le Thu T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K (2009) Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 53:5134–5140
82. Gerlich WH (2013) Medical virology of hepatitis B: how it began and where we are now. Virol J 10:239